Drug Discovery of Novel Oxindole Derivatives as Multitarget Modulators in Alzheimer's Disease
ISEF · 2026 Computational Biology and Bioinformatics
Overview
Alzheimer's disease (AD), a multifactorial neurodegenerative disorder, is associated with amyloid-beta aggregation, tau hyperphosphorylation, neuroinflammation, apoptosis, and endoplasmic reticulum (ER) stress. Current single-target therapies have limited clinical efficacy due to the interconnected nature of these pathological pathways. This study presents a computational biology framework to identify novel multitarget oxindole derivatives capable of modulating AD-relevant molecular networks. Initially, potential targets of oxindole derivatives were predicted using SwissTargetPrediction and cross-referenced with AD-associated genes from GeneCards to identify overlapping proteins. Protein–protein interaction networks were constructed to highlight hub proteins involved in neuroinflammation, apoptosis, and kinase signaling, followed by Gene Ontology and KEGG pathway enrichment analyses. Molecular docking studies with key proteins such as GSK3beta were performed to evaluate binding affinities, while 100 ns molecular dynamics simulations assessed complex stability. Binding free energies were estimated using MM/PBSA calculations. Virtual screening of 136 oxindole analogues expanded chemical diversity, and top candidates were evaluated experimentally in HT22 hippocampal neuronal cells under thapsigargin-induced ER stress. Preliminary results indicated that four compounds demonstrated low cytotoxicity and conferred protective effects, including modulation of beta-catenin signaling and inhibitory phosphorylation of GSK3beta. This integrated computational and experimental approach supports the development of multitarget therapeutics specifically for Alzheimer's disease.
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2024
Novel Drug Discovery Methodology Using Machine Learning for Gene Expression-Based Virtual Screening Predicts Novel Compounds To Reverse Alzheimer's Disease With Applications to Cancer and Longevity by Inhibiting CtBP2 Expression
ISEF · 2026
Discovering a Path from Molecular Modeling to Alzheimer's Phytotherapeutics: Characterizing Novel GSK3ß Inhibitors in silico and in vitro
ISEF · 2022
In silico High-Throughput Identification of Novel Dual Amyloid Beta and Tau Aggregation Inhibitors for Alzheimer's Disease Treatments
ISEF · 2018
Attacking Alzheimer's: Developing New Drugs Using Computational Modeling of Beta-Amyloid Protein Binding
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair